| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Veterans Affairs Medical Center (Dr. Adebonojo), and the Department of Surgery (Dr. Bowser), Wright State University School of Medicine, Dayton, OH; and the Department of Cardiothoracic Surgery (Drs. Moritz and Corcoran), Walter Reed Army Medical Center, Washington, DC.
Study objectives: This report reviews results of surgical management of lung cancer at a military medical center using the revised 1997 stage classification and determines the impact of the revised system on survival rates. It also compares our results with the recent reports from Japan and from a large, multinational study involving several institutions.
Design: Retrospective review.
Setting: Department of Cardiothoracic Surgery, Walter Reed Army Medical Center (WRAMC), Washington, DC.
Patients or participants: Active military members, their dependents, and eligible retired military members who were admitted to WRAMC for surgical treatment of lung cancer between January 1984 and December 1996.
Methods: Records of all patients who had surgical resection with intent to cure were reviewed. Data extracted included clinical and pathologic stages according to the 1997 revised stage classification. Survival probabilities for the stages were calculated by the Kaplan-Meier actuarial method. The log rank test was used to compare survival rates between stages and stage subsets. A p value < 0.05 was considered statistically significant.
Measurements and results: Five hundred fifty-two of the 1,398 patients with primary lung cancers underwent curative surgical resection (39.5%). The operative mortality was 2%. Using the revised 1997 stage classification, the survival rate for stage IA was 77%; IB, 62%; IIA, 57%; IIB, 47%; IIIA, 28%; IIIB, 20%; and IV, 0%. The overall actuarial 5-year and 10-year survival rates were 58% and 45%, respectively (median survival, 3.3 years; mean survival 3.9 ± 0.1 years).
Conclusions: Our results confirm the justification for the recent revisions in the staging system of lung cancer; however, there are still discrepancies that cannot be explained.
Key Words: lung cancer • lung cancer staging • lung neoplasm • surgery • survival rate
This article has been cited by other articles:
|
|
 |
|
  R. Timmerman, R. McGarry, C. Yiannoutsos, L. Papiez, K. Tudor, J. DeLuca, M. Ewing, R. Abdulrahman, C. DesRosiers, M. Williams, et al. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer J. Clin. Oncol., October 20, 2006; 24(30): 4833 - 4839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Asamura, T. Goya, Y. Koshiishi, Y. Sohara, R. Tsuchiya, E. Miyaoka, and The Japanese Joint Committee of Lung Cancer Regist How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 316 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Bronchogenic Carcinoma Cooperative Group of the Sp Survival of 2,991 Patients With Surgical Lung Cancer: The Denominator Effect in Survival Chest, October 1, 2005; 128(4): 2274 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Takeda, S. Fukai, H. Komatsu, E. Nemoto, K. Nakamura, M. Murakami, and Japanese National Chest Hospital Study Group Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pN0) Non-Small Cell Lung Cancer Ann. Thorac. Surg., April 1, 2005; 79(4): 1142 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lopez-Encuentra, R. Garcia-Lujan, J. Jose Rivas, J. Rodriguez-Rodriguez, J. Torres-Lanza, G. Varela-Simo, and Bronchogenic Carcinoma Cooperative Group of the Sp Comparison Between Clinical and Pathologic Staging in 2,994 Cases of Lung Cancer Ann. Thorac. Surg., March 1, 2005; 79(3): 974 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Timmerman, L. Papiez, R. McGarry, L. Likes, C. DesRosiers, S. Frost, and M. Williams Extracranial Stereotactic Radioablation: Results of a Phase I Study in Medically Inoperable Stage I Non-small Cell Lung Cancer Chest, November 1, 2003; 124(5): 1946 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Scott, J. Howington, and B. Movsas Treatment of Stage II Non-small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 188S - 201S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kameyama, C.-l. Huang, D. Liu, T. Okamoto, E. Hayashi, Y. Yamamoto, and H. Yokomise Problems related to TNM staging: Patients with stage III non-small cell lung cancer J. Thorac. Cardiovasc. Surg., September 1, 2002; 124(3): 503 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cai, K. Onoda, M. Takao, I.-Y. Kyoko, H. Shimpo, T. Yoshida, and I. Yada Degradation of Tenascin-C and Activity of Matrix Metalloproteinase-2 Are Associated with Tumor Recurrence in Early Stage Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1152 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yokoi, R. Tsuchiya, T. Mori, K. Nagai, T. Furukawa, S. Fujimura, K. Nakagawa, and Y. Ichinose Results of surgical treatment of lung cancer involving the diaphragm J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 799 - 805. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
